Cellomics and Beckman Coulter, Inc. Enter Into Comprehensive Strategic Relationship.

Business Editors and High-Tech Writers

PITTSBURGH, Pa. and FULLERTON, Calif.--(BW HealthWire)--June 22, 2000

Cellomics, Inc. and Beckman Coulter, Inc. (NYSE:BEC) announced today that they have entered into a long-term strategic relationship to offer Cellomics' High Content Screening technologies to Automated Drug Discovery customers. The agreement provides for:

-- Co-marketing of Cellomics' ArrayScan(R) II instrument and

application software, HitKit(TM) Reagents and certain

informatics products in North America and selected European

countries

-- A distribution arrangement in which Beckman Coulter is to

become exclusive distributor of the ArrayScan II and

ArrayScan(R) Kinetics Reader instruments, Cellomics(R) Store

and Cellomics(R) Screen informatics products and as the sales

agent for HitKit products

-- Formation of global Cell Technology Centers of Excellence

within academic and non-profit research institutions to advance

cell-based discovery technologies

-- Technology collaboration in mutual fields of interest.

"We are extremely pleased to have Beckman Coulter as a strategic corporate partner," stated Cellomics CEO, D. Lansing Taylor, Ph.D. "Their leading position in the automated high throughput drug discovery market, as well as their cell analysis capabilities with flow cytometry, makes this a very synergistic relationship."

"Cellomics' cell-based high content screening products are an important complement to our expanding efforts to provide complete solutions for efficient lead optimization." said Beckman Coulter Chairman, President and Chief Executive Officer John P. Wareham. "In the long term, we are optimistic that advances which result from the partnership -- both through the Cell Technology Centers and our own research organizations -- should further simplify and speed the drug discovery process."

Cellomics, Inc., a privately held corporation founded in October 1996, is focused on cell-based drug discovery. Cellomics' mission is to be the leader in generating high biological content data, information and knowledge from cells. Cellomics' products utilize novel fluorescence-based reagents in automated platforms, and cellular informatics in an effort to increase the productivity of the drug discovery process.

Beckman Coulter, Inc. is a leading provider of instrument systems and complementary products that simplify and automate processes in life science and clinical laboratories. The company's products are used throughout the world in all phases of the battle against disease, from pioneering medical research and drug discovery to diagnostic testing that aids in patient treatment. Annual sales for the company totaled $1.8 billion in 1999, with approximately half of this amount generated outside the United States.

For additional information, visit the Cellomics website at http://www.cellomics.com or the Beckman Coulter website at http://www.beckmancoulter.com